The relationship between NALP3 and autoinflammatory syndromes

International Journal of Molecular Sciences

Volumn 17, Issue 5, 2016, Pages

  Campbell, Lorna ^a   Raheem, Irfan ^a   Malemud, Charles J ^b   Askari, Ali D ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoinflammatory syndromes; Interleukin IL 1 ; NALP3 inflammasome

Indexed keywords

ADAPTOR PROTEIN; APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; AZATHIOPRINE; CANAKINUMAB; CELL ADHESION MOLECULE; COLCHICINE; CORTICOSTEROID; CRYOPYRIN; CYCLOOXYGENASE 2; CYTOKINE; ETANERCEPT; GLUTATHIONE TRANSFERASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; L SELECTIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; NITRIC OXIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROSTAGLANDIN E2; RECEPTOR INTERACTING PROTEIN SERINE THREONINE KINASE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; SERUM AMYLOID A; THROMBOCYTE ACTIVATING FACTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT; NLRP3 PROTEIN, HUMAN;

APOPTOSIS; AUTOINFLAMMATORY DISEASE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE DISORDER; CELL STRESS; CINCA SYNDROME; DOWN REGULATION; FAMILIAL MEDITERRANEAN FEVER; GENE EXPRESSION; GENE MUTATION; HETEROKARYON; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MEVALONATE KINASE DEFICIENCY; NONHUMAN; PAPA SYNDROME; PROTEIN BINDING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; ANIMAL; DRUG EFFECTS; GENETICS; HEREDITARY AUTOINFLAMMATORY DISEASES; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMASOMES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84967190667     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17050725     Document Type: Review

References (64)

1. Martinon, F.; Mayor, A.; Tschopp, J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 2009, 27, 229-265. [CrossRef] [PubMed]
2. Menu, P.; Vince, J.E. The NLRP3 inflammasome in health and disease: The good, the bad and the ugly. Clin. Exp. Immunol. 2011, 166, 1-15. [CrossRef] [PubMed]
3. Dinarello, C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009, 27, 519-550. [CrossRef] [PubMed]
4. Latz, E.; Xiao, T.S.; Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13, 397-411. [CrossRef] [PubMed]
5. Sharp, F.A.; Ruane, D.; Claass, B.; Creagh, E.; Harris, J.; Malyala, P.; Singh, M.; O’Hagan, D.T.; Pétrilli, V.; Tschopp, J. et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. USA 2009, 106, 870-875. [CrossRef] [PubMed]
6. Lamkanfi, M.; Malireddi, R.K.; Kanneganti, T.D. Fungal zymosan and mannan activate the cryopyrin inflammasome. J. Biol. Chem. 2009, 284, 20574-20581. [CrossRef] [PubMed]
7. 7receptor. EMBO J. 2006, 25, 5071-5082. [CrossRef] [PubMed]
8. Pelegrin, P.; Suprenant, A. Pannexin-1 couples to maitotoxin-and nigericin-induced interleukin-1β release through a dye uptake-independent pathway. J. Biol. Chem. 2007, 282, 2386-2394. [CrossRef] [PubMed]
9. Wei, Q.; Mu, K.; Li, T.; Zhang, Y.; Yang, Z.; Jia, X.; Zhao W.; Huai, W.; Guo, P.; Han, L. Dysregulation of the NLRP3 inflammasome in hepatic parenchymal cells during liver cancer progression. Lab. Investig. 2014, 94, 52-62. [CrossRef] [PubMed]
10. Heneka, M.T.; Kummer, M.P.; Stutz, A.; Delekate, A.; Schwartz, S.; Saecker, A.; Griep, A.; Axt, D.; Remus, A.; Tzeng, T.-C. et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493, 674-678. [CrossRef] [PubMed]
11. Imaeda, A.B.; Watanabe, A.; Sohail, M.A.; Mahmood, S.; Mohamadnejad, M.; Sutterwala, F.S.; Flavell, R.A.; Mehal W.Z. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Investig. 2009, 119, 305-314. [CrossRef] [PubMed]
12. Gasse, P.; Riteau, N.; Charron, S.; Girre, S.; Fick, L.; Pétrilli, V.; Tschopp, J.; Lagente, V.; Quesniaux, V.F.; Ryffel, B. et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 2009, 179, 903-913. [CrossRef] [PubMed]
13. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF consortium. Cell 1997, 90, 797-807.
14. Lidar, M.; Livneh, A. Familial Mediterranean fever: Clinical, molecular and management advancements. Nederl. Tijdschr. Geneesk. 2007, 65, 318-324.
15. Chae, J.J.; Wood, G.; Masters, S.L.; Richard, K.; Park, G.; Smith, B.J.; Kastner, D.L. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc. Natl. Acad. Sci. USA 2006, 103, 9982-9987. [CrossRef] [PubMed]
16. Omenetti, A. Increased NLPR3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: Correlation with MEFV genotype. Ann. Rheum. Dis. 2014, 73, 462-469. [CrossRef] [PubMed]
17. Yu, J.W.; Wu, J.; Zhang, Z.; Datta, P.; Ibrahimi, I.; Taniguchi, S.; Sagara, J.; Fernandes-Alnemri, T.; Alnemri, E.S. Cryopyrin and pyrin activate caspase-1, but not NF-κB, via ASC oligomerization. Cell Death Differ. 2006, 13, 236-249. [CrossRef] [PubMed]
18. Wang, D.Q.H.; Bonfrate, L.; de Bari, O.; Wang, T.; Portincasa, P. Familial Mediterranean fever: From pathogenesis to treatment. J. Genet. Syndr. Gene Ther. 2014, 5, 1-11.
19. Federici, S.; Martini, A.; Gattorno, M. The central role of anti-IL-1 blockade in the treatment of monogenic and multi-factorial autoinflammatory diseases. Front. Immunol. 2013, 4, 1-12. [CrossRef] [PubMed]
20. Ozdemir, O.; Sezgin, I.; Kurtulgan, H.K.; Candan, F.; Koksal, B.; Sumer, H.; Icagasioglu, D.; Uslu, A.; Yildiz, F.; Arslan, S. et al. Prevalence of known mutations in the MEFV gene in a population screening with high rate of carriers. Mol. Biol. Rep. 2011, 38, 3195-3200. [CrossRef] [PubMed]
21. Kuyuy, O.; Livneh, A.; Ben-David, A.; Kopolovic, J.; Volkov, A.; Shinar, Y.; Holtzman, E.; Dinour, D.; Ben-Zvi, I. Familial Mediterranean fever (FMF) with proteinuria: Clinical features, histology, predictors and prognosis in a cohort of 25 patients. J. Rheumatol. 2013, 40, 2083-2087. [CrossRef] [PubMed]
22. Lachmann, H.J.; Goodman, H.J.; Gilbertson, J.A.; Gallimore, J.R.; Sabin, C.A.; Gillmore, J.D.; Hawkins, P.N. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 2007, 356, 2361-2371. [CrossRef] [PubMed]
23. Ter Haar, N.M.; Frenkel, J. Treatment of hereditary autoinflammatory diseases. Curr. Opin. Rheumatol. 2014, 26, 252-258. [CrossRef] [PubMed]
24. Nuki, G. Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation. Curr. Rheumatol. Rep. 2008, 10, 218-227. [CrossRef] [PubMed]
25. Cerquaglia, C.; Diaco, M.; Nucera, G.; La Regina, M.; Montalto, M.; Manna, M. Pharmacological and clinical basis of treatment of familial Mediterranean fever (FMF) with colchicine or analogues: An update. Curr. Drug Targets-Inflamm. Allergy 2005, 4, 117-124. [CrossRef] [PubMed]
26. Ozen, S.; Bilginer, Y.; Aktay Ayaz, N.; Calguneri, M. Anti-interleukin 1 treatment for patients with Mediterranean fever resistant to colchicine. J. Rheumatol. 2011, 38, 516-518. [CrossRef] [PubMed]
27. Gul, A.; Ozdogan, H.; Erer, B.; Ugurlu, S.; Kasapcopur, O.; Davis, N.; Sevgi, S. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res. Ther. 2015, 17. [CrossRef] [PubMed]
28. Hentgen, V.; Grateau, G.; Kone-Paut, I.; Livneh, A.; Padeh, S.; Rozenbaum, M.; Amselem, S.; Gershoni-Baruch, R.; Touitou, I.; Ben-Chetrit, E. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin. Arthritis Rheum. 2013, 43, 387-391. [CrossRef] [PubMed]
29. Kuemmerle-Deschner, J.B. CAPS-Pathogenesis, presentation and treatment of an autoinflammatory disease. Semin. Immunopathol. 2015, 37, 377-385. [CrossRef] [PubMed]
30. Goldbach-Mansky, R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr. Rheumatol. Rep. 2011, 13, 123-131. [CrossRef] [PubMed]
31. Zeft, A.H. The Cleveland Clinic Center for Continuing Medical Education. 2015. Available online: http://www.clevelandclinicmeded.com/online/monograph/autoinflammatory/cryopyrin.asp (accessed on 18 April 2016).
32. Agostini, L.; Martinon, F.; Burns, K.; McDermott, M.F.; Hawkins, P.N.; Tschopp, J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004, 20, 319-325. [CrossRef]
33. Goldbach-Mansky, R.; Dailey, N.J.; Canna, S.W.; Gelabert, A.; Jones, J.; Rubin, B.I.; Kim, H.J.; Brewer, C.; Zalewski, C.; Wiggs, E. et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1β inhibition. N. Engl. J. Med. 2006, 355, 581-592. [CrossRef] [PubMed]
34. Dhimolea, E. Canakinumab. MAbs 2010, 2, 3-13. [CrossRef] [PubMed]
35. Smith, E.J.; Allantaz, F.; Bennett, L.; Zhang, D.; Gao, X.; Wood, G.; L Kastner, D.; Punaro, M.; Aksentijevich, I.; Pascual, V. et al. Clinical, molecular, and genetic characteristics of PAPA syndrome: A review. Curr. Genom. 2010, 11, 519-527. [CrossRef] [PubMed]
36. Lindor, N.M.; Arsenault, T.M.; Solomon, H.; Seidman, C.E.; McEvoy, M.T. A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. Mayo Clin. Proc. 1997, 72, 611-615. [CrossRef]
37. Shoham, N.G.; Centola, M.; Mansfield, E.; Hull, K.; Wood, G.; Wise, C.; Kastner, D.L. Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA 2003, 100, 13501-13506. [CrossRef] [PubMed]
38. Hong, J.B.; Su, Y.N.; Chiu, H.C. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): Report of a sporadic case without an identifiable mutation in the CD2BP1 gene. J. Am. Acad. Dermatol. 2009, 61, 533-535. [CrossRef] [PubMed]
39. Demidowich, A.P.; Freeman, A.F.; Kuhns, D.B.; Aksentijevich, I.; Gallin, J.I.; Turner, M.L.; Kastner, D.L.; Holland, S.M. Brief Report: Genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum. 2012, 64, 2022-2027. [CrossRef] [PubMed]
40. Brenner, M.; Ruzicka, T.; Plewig, G.; Thomas, P.; Herzer, P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 2009, 161, 1199-1201. [CrossRef] [PubMed]
41. Dierselhuis, M.P.; Frenkel, J.; Wulffraat, N.M.; Boelens, J.J. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology 2005, 44, 406-468. [CrossRef] [PubMed]
42. Haas, D.; Hoffman, G. Mevalonate kinase deficiencies: From mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Otphanet. J. Rare Dis. 2006, 1, 1-5.
43. Cuisset, L.; Drenth, J.P.H.; Simon, A.; Vincent, M.F.; van der Velde Visser S.; van der Meer, J.W.M.; Grateau, G.; Delpech, M. Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. Eur. J. Hum. Genet. 2001, 9, 260-266. [CrossRef] [PubMed]
44. Celsi, F.; Piscianz, E.; Romano, M.; Crovella, S. Knockdown of MVK does not lead to changes in NALP3 expression or activation. J. Inflamm. (Lond.) 2015, 12. [CrossRef] [PubMed]
45. Bodar, E.J.; Kuijk, L.M.; Drenth, J.P.H.; van der Meer, J.W.M.; Simon, A.; Frenkel, J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann. Rheum. Dis. 2011, 70, 2155-2158. [CrossRef] [PubMed]
46. Aróstegui, J.I.; Calvo, I.; Anton, J.; Robles, A.; Yagüe, J.; Viana, R.; Tseng, L.; Abrams, K. Canakinumab treatment In active hyper-IgD with periodic fever syndrome. Arthritis Rheum. 2013, 65, 1783.
47. Arkwright, P.D.; Mcdermott, M.F.; Houten, S.M.; Frenkel, J.; Waterham, H.R.; Aganna, E.; Hammond, L.J.; Mirakian, R.M.; Tomlin, P.I.; Vijaydurai, P.I. et al. Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin. Exp. Immunol. 2002, 130, 484-488. [CrossRef] [PubMed]
48. Shendi, H.M.; Devlin, L.A.; Edgar, J.D. Interleukin 6 blockade for hyperimmunoglobulin D and periodic fever syndrome. J. Clin. Rheumatol. 2014, 20, 103-105. [CrossRef] [PubMed]
49. Toro, J.R.; Aksentijevich, I.; Hull, K.; Dean, J.; Kastner, D. Tumor necrosis factor receptor-associated periodic syndrome: A novel syndrome with cutaneous manifestations. Arch. Dermatol. 2000, 136, 1487-1494. [CrossRef] [PubMed]
50. Williamson, L.M.; Hull, D.; Mehta, R.; Reeves W.G.; Robinson, B.H.; Toghill, P.J. Familial Hibernian fever. Q. J. Med. 1982, 51, 469-480. [PubMed]
51. McDermott, M.F.; Aksentijevich, I.; Galon, J.; McDermott, E.M.; Ogunkolade, B.W.; Centola, M.; Mansfield, E.; Gadina, M.; Karenko, L.; Pettersson, T. et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97, 133-144. [CrossRef]
52. Yao, Q.; Furst, D.E. Autoinflammatory diseases: An update of clinical and genetic aspects. Rheumatology 2008, 47, 946-951. [CrossRef] [PubMed]
53. Álvarez, S.; Muñoz-Fernández, M.Á. TNF-A may mediate inflammasome activation in the absence of bacterial infection in more than one way. PLoS ONE 2013, 8, E71477. [CrossRef] [PubMed]
54. Gattorno, M.; Pelagatti, M.A.; Meini, A.; Obici, L.; Barcellona, R.; Federici, S.; Buoncompagni, A.; Plebani, A.; Merlini, G.; Martini, A. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008, 58, 1516-1520. [CrossRef] [PubMed]
55. Drewe, E.; McDermott, E.M.; Powell, P.T.; Isaacs, J.D.; Powell, R.J. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumor necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): Clinical and laboratory findings in a series of seven patients. Rheumatology 2003, 42, 235-239. [PubMed]
56. Jacobelli, S.; André, M.; Alexandra, J.F.; Dodé, C.; Papo, T. Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology 2007, 46, 1211-1212. [CrossRef] [PubMed]
57. Bulua, A.C.; Mogul, D.B.; Aksentijevich, I.; Singh, H.; He, D.Y.; Muenz, L.R.; Ward, M.M.; Yarboro, C.H.; Kastner, D.L.; Siegel, R.M. et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: A prospective, open-label, dose-escalation study. Arthritis Rheum. 2012, 64, 908-913. [CrossRef] [PubMed]
58. Nedjai, B.; Hitman, G.A.; Quillinan, N.; Coughlan, R.J.; Church, L.; McDermott, M.F.; Turner, M.D. Proinflammatory action of the anti-inflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2009, 60, 619-625. [CrossRef] [PubMed]
59. Bernard, D.; Quatannens, B.; Begue, A.; Vandenbunder, B.; Abbadie, C. Antiproliferative and antiapoptotic effects of cRel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res. 2001, 61, 2656-2664. [PubMed]
60. Sanjabi, S.; Hoffmann, A.; Liou, H.C.; Baltimore, D.; Smale, S.T. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc. Natl. Acad. Sci. USA 2000, 97, 12705-12710. [CrossRef] [PubMed]
61. Davis, B.K.; Wen, H.; Ting, J.P. The inflammasome NLRs in immunity, inflammation and associated diseases. Annu. Rev. Immunol. 2011, 29, 707-735. [CrossRef] [PubMed]
62. Dinarello, C.A. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am. J. Clin. Nutr. 2006, 83, 447S-455S. [PubMed]
63. Martinon, F. Signaling by ROS drives inflammasome activation. Eur. J. Immunol. 2010, 40, 616-619. [CrossRef] [PubMed]
64. He, Y.; Zeng, M.Y.; Yang, D.; Motro, B.; Núñez, G. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 2016, 530, 354-357. [CrossRef] [PubMed]